Pharmacovigilance – News and Features

News
Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
Pharmatek now offers contract cytotoxic & high- potent analytical, formulation and manufacturing services.

News
Quark Pharmaceuticals Extends Research Agreement with State University of New York
Quark's siRNA compounds for acute hearing loss slated for IND filing by year- end 2007.

News
Abraxis Acquires Exclusive Worldwide Intellectual Property Rights from the Buck Institute
The agreement provides Abraxis with the exclusive property rights for technologies designed to generate therapeutics and identify new drug discovery targets.

News
Quark Pharmaceuticals Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure
Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA.

News
Cell Therapeutics Announces Agreement to Acquire Systems Medicine
Under the terms of the agreement, SMi will continue to operate as a wholly-owned subsidiary of CTI, utilizing its genomic-based platform to guide development of CTI's oncology products.

News
MPI Research Continues Toxicology Expansion
As part of a series of planned expansions, MPI Research announces the immediate availability of additional toxicology capacity.

News
CellCyte Executives Highlight Plans for Breakthrough Stem Cell-Enabling Therapeutic Products and Devices
In an interview published in The Wall Street the executives gave their views about moving quickly into a global leadership position in the emerging field of regenerative medicine with the company's stem cell-enabling therapeutic products and devices.

News
Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin’s Lymphoma Meets Primary Endpoint
Genzyme completes its phase 3 trial of Mozobil™ in non-Hodgkin’s lymphoma, and the trial has robustly met its primary and secondary endpoints.

News
MS Society Announces $2.4M to Continue Ottawa Bone Marrow Stem Cell Transplant Trial
The grant will continue a closely-watched clinical trial involving an experimental bone marrow stem cell transplant therapy at MS Society of Canada.

News
Personalized Medicine: Milestone in the Therapy Control of Humanized Antibodies
CENiMED, BioTeZ and Invitek announce their cooperation to develop, produce and market the Recovery-ELISAs for the therapy control of humanized antibodies.
Advertisement